Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Pfizer : MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:13pm CEST

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say theyll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers.

The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative.

Pfizers investigational therapies to be used in the trials include Bavencio (avelumab), a PD-L1 inhibitor; Glasdegib (PF-04449913), an investigational oral, smoothened (SMO) inhibitor; Mylotard (gemtuzumab ozogamicin), an antibody-drug conjugate; PF-04518600, an investigational OX40 agonist, and Utomilumab (a non-proprietary name for PF-05082566), an investigational CD137 agonist.

The first study is expected to enroll up to 188 patients with solid tumors, included in seven treatment groups of therapeutic agents alone or in combination with radiotherapy.

This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies, Dr. Aung Naing, associate professor of investigational cancer therapeutics at Houston-based MD Anderson and head of the solid tumor program, said in a press release. The studies are designed to hone in on specific combinations and tumor types, and explore unique mechanisms of response and resistance to immunotherapies. Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.

The second study, designed to enroll 159 patients with acute myeloid leukemia (AML), will have eight different treatment arms. In addition, three other studies will evaluate Pfizer agents in blood cancer patients.

This series of Phase 1b trials will involve an accelerated series of combination immunotherapy trials for acute myeloid leukemia (AML) and solid tumors, said Dr. Naval Daver, associate professor of leukemia at MD Anderson and leading investigator at the blood cancer clinical trial. Our aim is to deliver new therapeutic solutions to our patients through this uniquely designed clinical trial program.

Most of the trials are anticipated to be initiated before the end of 2017.

Pfizer believes that meaningful treatment advancements for patients with blood cancers will come from novel combinations of immuno-oncology agents and targeted therapies, said Dr. Chris Boshoff, senior vice-president and head of immuno-oncology, early development and translational oncology at Pfizer. We are delighted to work with MD Anderson one of the worlds best cancer research institutions to explore unique combinations that may have a significant impact for patients.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
02:37aPFIZER : to hire 350 workers in McPherson, plans Wichita job fair
09/21PFIZER : Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal..
09/20PFIZER : Studies from Pfizer Update Current Data on Kinase Inhibitors (Updates o..
09/20PFIZER : Trademark Application for "VIZIMPRO" Filed by Pfizer
09/20PFIZER : Studies from Pfizer Yield New Data on Immunoglobulins (Rational optimiz..
09/20PFIZER : Trademark Application for "FLAGYL" Filed by Pfizer
09/20PFIZER : U.S. Patents Awarded to Inventors in Connecticut (Sept. 20)
09/20PFIZER : U.S. Patents Awarded to Inventors in Massachusetts (Sept. 20)
09/20PFIZER : Research Results from Pfizer Update Understanding of HIV/AIDS (No Clini..
09/20Animal health firm Elanco surges 41 percent on debut
More news
News from SeekingAlpha
08:26aSTOCKS TO WATCH : Calling Up Animal Spirits 
09/20Arvinas Holding Prepares Terms For $100 Million IPO 
09/20Entasis Therapeutics Readies $75 Million IPO Plan 
09/20FDA grants Breakthrough Therapy designation to Pfizer's PF-06482077 
09/19PFIZER AND CONATUS : Emricasan And NASH 
Financials ($)
Sales 2018 54 227 M
EBIT 2018 20 582 M
Net income 2018 13 123 M
Debt 2018 24 897 M
Yield 2018 3,11%
P/E ratio 2018 19,64
P/E ratio 2019 18,11
EV / Sales 2018 5,22x
EV / Sales 2019 4,97x
Capitalization 258 B
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 42,4 $
Spread / Average Target -3,8%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER21.65%258 285
JOHNSON & JOHNSON1.62%383 312
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092
AMGEN17.94%132 756